Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Peripheral Arterial Disease, Diabetic Foot
Interventions: PDA-002, Placebo; Biological · Other
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more

Conditions: Higher-risk Myelodysplastic Syndromes
Interventions: AK117, Placebo, Azacitidine; Drug
Lead sponsor: Akeso; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 11 more

Conditions: Bunion, Hallux Valgus
Interventions: SKY0402, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: SAR231893, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Bakersfield, California • Culver City, California • Los Angeles, California + 9 more

Conditions: Knee Osteoarthritis
Interventions: Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline; Device · Drug
Lead sponsor: Dustin L. Richter, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Steatohepatitis
Interventions: AZD7503; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more

Conditions: Brain Injuries
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 20
States / cities: Mobile, Alabama • Tucson, Arizona • Colton, California + 16 more

Conditions: COPD
Interventions: Testosterone Enanthate, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions: Satralizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 20
States / cities: Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more

Conditions: Rheumatoid Arthritis
Interventions: Secukinumab (AIN457), Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 25
States / cities: Peoria, Arizona • Santa Monica, California • Upland, California + 20 more

Conditions: Pneumonia
Interventions: CM4620-IE (Injectable Emulsion), Placebo; Drug
Lead sponsor: CalciMedica, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, End Stage Renal Disease
Interventions: Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Dengue Fever
Interventions: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 13 Years to 63 Years
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Gynecologic Cancer, Post-operative Pain
Interventions: Bupivicaine, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Dengue Virus
Interventions: Investigational Vaccine for DEN1, Placebo injection; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Burlington, Vermont

Conditions: Kidney Transplant
Interventions: Berinert, Placebo for Berinert; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
Interventions: Placebo, PF-04856883; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Chula Vista, California • Miami, Florida • Miramar, Florida + 4 more

Conditions: Knee Osteoarthritis
Interventions: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP; Drug
Lead sponsor: Nova Vita Laboratory; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK2376497, 0.9% sodium chloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Varicella
Interventions: TNM005, Placebo, VariZIG; Drug
Lead sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Opioid Use, Pain, Hypogonadism, Male
Interventions: Testosterone Undecanoate 250 MG/ML, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lower Back Pain
Interventions: CNTX-3001, Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Napa, California

Search by objective public record fields.

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Study of Postoperative Analgesia in Bunionectomy

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Study of NNZ-2566 in Patients With Traumatic Brain Injury

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

A Study of Auxora in Patients With Critical COVID-19 Pneumonia

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery

A Study of TAK-951 in Healthy Adults

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

NANOVAE to Treat Knee Osteoarthritis (KOA)

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain